Oarsman Capital’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $4.26M | Buy |
19,598
+542
| +3% | +$120K | 0.53% | 33 |
|
|
2025
Q4 | $4.35M | Buy |
19,056
+825
| +5% | +$188K | 0.57% | 28 |
|
|
2025
Q3 | $4.22M | Buy |
18,231
+508
| +3% | +$103K | 0.59% | 28 |
|
|
2025
Q2 | $3.29M | Buy |
17,723
+121
| +0.7% | +$22.5K | 0.52% | 34 |
|
|
2025
Q1 | $3.69M | Sell |
17,602
-15
| -0.1% | -$2.92K | 0.66% | 26 |
|
|
2024
Q4 | $3.13M | Sell |
17,617
-1,471
| -8% | -$270K | 0.55% | 31 |
|
|
2024
Q3 | $3.77M | Buy |
19,088
+306
| +2% | +$57.1K | 0.69% | 28 |
|
|
2024
Q2 | $3.22M | Buy |
18,782
+1,232
| +7% | +$204K | 0.71% | 30 |
|
|
2024
Q1 | $3.2M | Sell |
17,550
-5,738
| -25% | -$989K | 0.76% | 30 |
|
|
2023
Q4 | $3.61M | Buy |
23,288
+797
| +4% | +$116K | 0.96% | 24 |
|
|
2023
Q3 | $3.35M | Buy |
22,491
+127
| +0.6% | +$18.6K | 1.4% | 15 |
|
|
2023
Q2 | $3.01M | Sell |
22,364
-2,059
| -8% | -$302K | 1.32% | 17 |
|
|
2023
Q1 | $3.89M | Buy |
24,423
+470
| +2% | +$71.9K | 1.82% | 13 |
|
|
2022
Q4 | $3.87M | Sell |
23,953
-743
| -3% | -$114K | 1.98% | 13 |
|
|
2022
Q3 | $3.31M | Buy |
24,696
+66
| +0.3% | +$9.47K | 1.78% | 14 |
|
|
2022
Q2 | $3.77M | Sell |
24,630
-2,245
| -8% | -$343K | 1.87% | 11 |
|
|
2022
Q1 | $4.36M | Sell |
26,875
-1,597
| -6% | -$232K | 1.7% | 10 |
|
|
2021
Q4 | $3.85M | Sell |
28,472
-1,988
| -7% | -$235K | 1.52% | 13 |
|
|
2021
Q3 | $3.29M | Sell |
30,460
-28
| -0.1% | -$3.2K | 1.33% | 15 |
|
|
2021
Q2 | $3.43M | Sell |
30,488
-1,352
| -4% | -$152K | 1.36% | 13 |
|
|
2021
Q1 | $3.45M | Sell |
31,840
-5,011
| -14% | -$536K | 1.49% | 14 |
|
|
2020
Q4 | $3.95M | Sell |
36,851
-2,264
| -6% | -$218K | 1.53% | 11 |
|
|
2020
Q3 | $3.43M | Sell |
39,115
-1,016
| -3% | -$95.7K | 1.54% | 14 |
|
|
2020
Q2 | $3.94M | Buy |
40,131
+19,555
| +95% | +$1.72M | 1.95% | 9 |
|
|
2020
Q1 | $1.57M | Sell |
20,576
-16,123
| -44% | -$1.37M | 1.45% | 24 |
|
|
2019
Q4 | $3.25M | Buy |
36,699
+1,929
| +6% | +$160K | 1.49% | 17 |
|
|
2019
Q3 | $2.63M | Buy |
34,770
+1,887
| +6% | +$129K | 1.25% | 21 |
|
|
2019
Q2 | $2.39M | Sell |
32,883
-65
| -0.2% | -$5.11K | 1.08% | 28 |
|
|
2019
Q1 | $2.65M | Sell |
32,948
-12,989
| -28% | -$1.06M | 1.26% | 21 |
|
|
2018
Q4 | $4.24M | Buy |
45,937
+1,087
| +2% | +$95.6K | 2.17% | 5 |
|
|
2018
Q3 | $4.24M | Buy |
44,850
+144
| +0.3% | +$13.7K | 1.71% | 13 |
|
|
2018
Q2 | $4.14M | Buy |
44,706
+1,555
| +4% | +$152K | 1.88% | 8 |
|
|
2018
Q1 | $4.08M | Sell |
43,151
-1,220
| -3% | -$134K | 1.86% | 11 |
|
|
2017
Q4 | $4.29M | Sell |
44,371
-347
| -0.8% | -$32.7K | 1.85% | 10 |
|
|
2017
Q3 | $3.97M | Buy |
44,718
+1,492
| +3% | +$114K | 1.68% | 12 |
|
|
2017
Q2 | $3.13M | Buy |
43,226
+1,191
| +3% | +$80.1K | 1.43% | 20 |
|
|
2017
Q1 | $2.74M | Buy |
42,035
+5,094
| +14% | +$320K | 1.27% | 22 |
|
|
2016
Q4 | $2.31M | Sell |
36,941
-3,736
| -9% | -$228K | 1.49% | 18 |
|
|
2016
Q3 | $2.57M | Buy |
40,677
+444
| +1% | +$28.7K | 1.31% | 19 |
|
|
2016
Q2 | $2.49M | Buy |
40,233
+1,154
| +3% | +$70.3K | 1.29% | 19 |
|
|
2016
Q1 | $2.23M | Buy |
39,079
+13,666
| +54% | +$762K | 1.19% | 20 |
|
|
2015
Q4 | $1.5M | Buy |
25,413
+345
| +1% | +$19.9K | 0.84% | 41 |
|
|
2015
Q3 | $1.36M | Buy |
25,068
+4
| +0% | +$260 | 0.81% | 41 |
|
|
2015
Q2 | $1.68M | Buy |
25,064
+469
| +2% | +$30.6K | 1.15% | 21 |
|
|
2015
Q1 | $1.44M | Sell |
24,595
-34
| -0.1% | -$2.05K | 0.99% | 32 |
|
|
2014
Q4 | $1.61M | Sell |
24,629
-315
| -1% | -$19.9K | 1.16% | 22 |
|
|
2014
Q3 | $1.44M | Buy |
24,944
+676
| +3% | +$37.5K | 1.06% | 28 |
|
|
2014
Q2 | $1.37M | Buy |
24,268
+1,663
| +7% | +$87.2K | 0.99% | 29 |
|
|
2014
Q1 | $1.16M | Buy |
22,605
+1
| +0% | +$51 | 0.9% | 35 |
|
|
2013
Q4 | $1.19M | Buy |
22,604
+11
| +0% | +$541 | 0.96% | 33 |
|
|
2013
Q3 | $1.01M | Buy |
22,593
+901
| +4% | +$39.9K | 0.88% | 40 |
|
|
2013
Q2 | $897K | Buy |
+21,692
| New | +$949K | 0.85% | 42 |
|
Other funds holding ABBV
VCM
VPM
Oarsman Capital's ABBV Position: Q1 2026 in Review
Oarsman Capital increased its AbbVie (ABBV) stake by 2.8% in Q1 2026, buying an estimated $120K and bringing the position to 19,598 shares worth $4.26M. The position accounts for 0.53% of the portfolio, ranked #33.
Oarsman Capital first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $4.36M in Q1 2022. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Oarsman Capital held 19,598 shares of AbbVie worth $4.26M as of Q1 2026.
- Oarsman Capital bought 542 AbbVie shares in Q1 2026, an estimated $120K.
- AbbVie made up 0.53% of Oarsman Capital's portfolio in Q1 2026, its #33 holding.
- Oarsman Capital first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
- Oarsman Capital's AbbVie position peaked at $4.36M in Q1 2022.
- 4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Oarsman Capital's 13F filing for Q1 2026, filed 28 Apr 2026.